TLSI Earnings Prediction
The chart below shows how TLSI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TLSI sees a -2.97% change in stock price 10 days leading up to the earnings, and a -13.04% change 10 days following the report. On the earnings day itself, the stock moves by -0.58%. This data can give you a slight idea of what to expect for the next quarter's release.
TLSI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
7.35M
41.52%
-0.20%
Gross Margin
86.34%
-2.62%
-1.46%
Operating Margin
-118.91%
-66.83%
7.13%
Net Margin
-32.64%
18.95%
-44.52%
EPS
-0.12
-14.29%
-42.86%
No Data Available
TLSI Earnings Analysis
TriSalus Life Sciences, Inc. Common Stock Corporation (TLSI.O) Earnings Conference Call
Positive
TriNav Technology Success: TriSalus achieved outstanding performance in Q3 2024, driven by the continued success of the TriNav technology in the U.S.
Q3 Revenue Surge: Revenue reached $7.3 million in Q3, reflecting a 42% increase compared to the same period in 2023.
Year-to-Date Revenue Growth: Year-to-date revenue stands at $21.2 million, reflecting a 66% growth compared to the nine months of last year.
Hospital Account Growth: In Q3, TriSalus added 42 net new hospital accounts, increasing utilization to 15.3 units per account, up from 13.5 units per account in Q3 2023.
R&D Expense Reduction: R&D expenses for the third quarter totaled $4.2 million, down 56% compared to the same period in 2023, reflecting the completion of patient enrollment in the PERIO Phase I trials.
Negative
Operating Loss Improvement: Operating losses in Q3 and year-to-date were negative $8.7 million and negative $28.6 million, respectively, an improvement from $18.8 million in 2023 third quarter and $40.2 million in the first nine months of 2023.
Administrative Expense Reduction: General and administrative expenses for Q3 and year-to-date totaled $4.7 million and $13.3 million, marking a decrease of 48% in Q3 and 24% in the first nine months compared to the same periods in 2023.
R&D Expense Decline: R&D expenses for the third quarter and year-to-date totaled $4.2 million and $14.7 million, down 56% and 33%, respectively, compared to the same period in 2023.
Cash Burn Analysis: Cash burn in the third quarter was at a tad over $11 million, with expectations for the fourth quarter to be down in the range of $4 million to $4.5 million.
Decline in Operating Expenses: Operating expenses should decline by 20%, reflecting reduced clinic costs from the conclusion of the PERIO Phase I trials and lower G&A expenses following one-time costs associated with becoming a public company.
TLSI FAQs
How does TLSI typically perform around its earnings report dates?
Is TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TLSI Earning Call Sentiment
TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TLSI.O
-5.3%Positive
The earnings report shows strong financial metrics with a 42% revenue growth and improved operating losses. Despite some uncertainties in the Q&A, like unclear partnership plans and pancreatic treatment efficacy, the overall sentiment is positive due to the robust financial performance and optimistic growth strategy. The company's focus on achieving EBITDA positivity by 2025 and strategic funding plans further support a positive outlook. Given these factors, the stock is likely to see a positive movement in the short term, potentially within the 2% to 8% range.
